Coldstream Capital Management Inc. Buys 653 Shares of Kenvue Inc. (NYSE:KVUE)

Coldstream Capital Management Inc. boosted its stake in Kenvue Inc. (NYSE:KVUE) by 2.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,017 shares of the company’s stock after purchasing an additional 653 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Kenvue were worth $602,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Leo Wealth LLC grew its stake in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after buying an additional 481 shares during the period. Alerus Financial NA grew its stake in Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares during the period. Massmutual Trust Co. FSB ADV increased its holdings in shares of Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after acquiring an additional 492 shares in the last quarter. Wolff Wiese Magana LLC raised its position in shares of Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares during the period. Finally, Marathon Capital Management lifted its holdings in shares of Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of Kenvue stock opened at $22.21 on Friday. The business’s fifty day simple moving average is $22.95 and its 200 day simple moving average is $21.17. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The firm has a market capitalization of $42.58 billion, a P/E ratio of 40.38, a price-to-earnings-growth ratio of 2.02 and a beta of 1.36.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.31 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.69%. The ex-dividend date was Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KVUE. Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. upped their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research note on Thursday. Finally, Jefferies Financial Group started coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.